Dispen3D is setting new standards in single-cell biology, enabling researchers to conduct high-precision experiments that drive advancements in drug discovery, personalized medicine, and regenerative therapies.
SGN-516 by SGN Nanopharma for Diabetic Neuropathy: Likelihood of Approval
Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug